Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 4/20 | 0.31 |
| ▸ | CDK8 | P49336 | 4/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347966 | 0.86 | OTUD7B (0.43) | OTUD7BCALCRLSPRCCNCCDK8 | |
| SCHEMBL21225565 | 0.78 | CRBN (0.35) | OTUD7BMTNR1AMTNR1BSPRL3MBTL1 | |
| SCHEMBL24339013 | 0.72 | OTUD7B (0.38) | OTUD7BSPRCCNCCDK8CRBN | |
| SCHEMBL19852843 | 0.70 | OTUD7B (0.42) | OTUD7BRORCCRBNCHRNB2CHRNA3 | |
| SCHEMBL18711886 | 0.70 | OTUD7B (0.46) | OTUD7BSPRCCNCCDK8 | |
| SCHEMBL13207170 | 0.69 | JAK2 (0.40) | OTUD7BL3MBTL1CCNCCDK8 | |
| SCHEMBL4072997 | 0.68 | OTUD7B (0.47) | OTUD7BCALCRLSPRCCNCCDK8 | |
| SCHEMBL24339014 | 0.68 | OTUD7B (0.39) | OTUD7BCALCRLSPRCCNCCDK8 | |
| SCHEMBL24339054 | 0.68 | OTUD7B (0.39) | OTUD7BRORCCALCRLSPRCCNC | |
| SCHEMBL29890275 | 0.67 | OTUD7B (0.46) | OTUD7BCALCRLSPRCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | OTUD7B 3145/4885RORC 427/4885CALCRL 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.